Highest-materiality recent filing
Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401
Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.
Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026
Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.
Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026
Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027
Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.
Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026
Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.
Tenaya Therapeutics prices $60M public offering of 50M units at $1.20/unit; warrants at $1.50
Gross proceeds ~$60M from 50M units, each unit = 1 share + 1 warrant (5-yr, $1.50 exercise).
FDA lifts clinical hold on TN-201; TN-401 shows positive interim data in ARVC patients
FDA removed clinical hold on MyPEAK-1 trial for TN-201 gene therapy; protocol amendments implemented, dosing to resume.
Tenaya reports Q3 net loss $20.3M; FDA places clinical hold on TN-201 MyPEAK-1 trial
Net loss $20.3M ($0.12/share) vs $25.6M ($0.30) in Q3 2024; cash $56.3M, sufficient into H2 2026.
FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request
FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.
Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025
Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026
Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
Tenaya receives Nasdaq bid price deficiency notice; must regain compliance by Oct 13, 2025
Closing bid price of TNYA common stock below $1.00 for 30 consecutive business days through April 12, 2025.
Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026
Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
Tenaya Therapeutics prices $52.5M public offering of units with warrants
Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients
TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs
Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025
Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.
Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024
Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).
Gross proceeds expected ~$50M from 8,888,890 common shares at $4.50 and 2,222,271 pre-funded warrants at $4.499.
Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial
Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.
Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track
Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.
Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023
Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.
Tenaya Therapeutics prices public offering of ~28.85M shares/warrants for ~$75M gross proceeds
Priced public offering of 22,613,307 common shares at $2.60 and 6,236,693 pre-funded warrants at $2.599 per warrant.
Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track
Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.
Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track
Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.
Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing
Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.
Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.
Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company
Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.
Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya
On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.
On June 25, 2024, Jin-Long Chen submitted his resignation as a director of Tenaya Therapeutics, Inc.
On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).
On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.
appointed Karah Parschauer to the Board and as a member of the audit committee of the Board
On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.
On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director
Max materiality 0.85 · Median 0.60 · Most common event earnings